PDMR Dealing

RNS Number : 8168L

Oxford BioDynamics PLC

10 September 2019

 

10 September 2019

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

PDMR Dealing

Oxford BioDynamics Plc (AIM: OBD) announces that it has today received notice that Vulpes Life Sciences Fund, which is controlled by Non-Executive Director, Stephen Diggle, has purchased 11,406 Ordinary Shares of 1 pence each at a price of 87p per share.

Following this transaction, Vulpes Life Sciences Fund is interested in 11,783,361 Ordinary Shares, representing approximately 12.73% of the Company's current issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Stephen Diggle
2	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oxford BioDynamics Plc
b)	LEI	2138005Y1TK258O5U928
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 1 pence each ISIN:   GB00BD5H8572
b)	Nature of the transaction	Acquisition of ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 0.87 11,406
d)	Aggregated information - Aggregated volume - Price	Price Volume 0.87 11,406
e)	Dates of the transactions	9 September 2019
f)	Place of the transaction	Outside a trading venue

For further details please contact:

Oxford BioDynamics Plc Christian Hoyer Millar, CEO Paul Stockdale, CFO	[phone]
Shore Capital Nominated Adviser and Broker Stephane Auton Edward Mansfield	[phone]
FTI Consulting Financial Public Relations Adviser Brett Pollard Natalie Garland-Collins	[phone]

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

 

END

 

 

DSHLMMLTMBTBMTL